Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
Status:
Terminated
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
The aim of this pilot study is to investigate the application of proteasome inhibitor
Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with
therapy-refractory antibody-mediated autoimmune diseases. The investigators hypothesis is
that the proteasome inhibition will lead to reduced antibody titers and improved clinical
outcome.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
NeuroCure Clinical Research Center, Charite, Berlin Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)